Scienza e Tecnologia
XNK Therapeutics partners with Karolinska Institutet on Phase II study in patients with multiple myeloma with support from Sanofi
"Performing this Phase II study together with Karolinska Institutet is an important step for XNK in its ambition to combat multiple myeloma," said Johan Liwing, CEO of XNK Therapeutics. "Combining our efforts together with the present partners highlights just how far XNK has progressed with its patented technology platform."
"We really look forward towards conducting this exciting clinical trial including partnering with XNK Therapeutics," said Hareth Nahi , Associate Professor at KI.
The study ISA-HC-NK (EudraCT: 2020-000994-26) compares XNK's leading drug candidate combined with isatuximab vs isatuximab as a consolidation treatment following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma.
XNK is a collaborative partner within NextGenNK, a recently established Competence Center for the development of next-generation NK cell-based cancer immunotherapies coordinated by Karolinska Institutet and supported by Sweden's Innovation Agency (Vinnova).
Johan Liwing, CEO, XNK Therapeutics
Tel: +46 706 70 36 75
E-mail: johan.liwing@xnktherapeutics.com
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company's platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow's cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden . For more info, please visit www.xnktherapeutics.com .
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/xnk-therapeutics-ab/r/xnk-therapeutics-partners-with-karolinska-institutet-on-phase-ii-study-in-patients-with-multiple-mye,c3296450
The following files are available for download: